济南阳痿做手术济南尿道口发炎红肿,济南射精早,济南尿道口绿色分泌物,济南阳萎的调理自,济南阴茎有点刺{痛},济南看前列腺医院排名,济南看男科病到那家医院

WASHINGTON, July 20 (Xinhua) -- The loss of a protein that coats sperm may explain a significant proportion of infertility in men worldwide, according to a study by an international team of researchers led by University of California Davis.A paper describing the work was published Wednesday in the journal Science Translational Medicine. The research could open up new ways to screen and treat couples for infertility.The gene DEFB126 encodes a protein called Beta Defensin 126, which coats the surface of sperm and helps it penetrate cervical mucus in the female. A survey of samples from the U.S., Britain and China showed that as many as a quarter of men worldwide carry two copies of the defective gene.In the new study, researchers found that men with a muted DEFB126 lack Beta Defensin 126, making it much more difficult for sperm to swim through the mucus and eventually join with an egg.Examining 500 newly married Chinese couples, researchers found that the lack of Beta Defensin 126 in men with the DEFB126 mutation lowered fertility (even among men that did not display other deficiencies usually associated with infertility, like inadequate semen volume and low sperm motility). Wives of men with the Beta Defensin 126 variant were significantly less likely to become pregnant than were other couples, and 30 percent less likely to have a birth.This genetic variation in DEFB126 likely accounts for many unexplained cases of infertility, researchers say. They hope next to work with a major infertility program in the U.S. to further explore the role of the mutation.

BEIJING, Sept. 20 (Xinhuanet)-- Google's executive chairman Eric Schmidt is to face a Senate hearing on whether the company is abusing its dominance in Internet search, according to media reports on Tuesday.At the Wednesday's hearing before the Senate Judiciary Committee's antitrust panel, Schmidt will argue that critics are wrong to say Google gives preference to its own products, instead, Google is just trying to deliver the best-cultivated search results for users. The issue of search ranking is a touchy subject with Google, which says its algorithm is devised to give users the most useful result so they will come back.Another focal point of the hearing, which Schmidt concerned most is "scrapers", those who game its search algorithm, for example, taking commonly searched words, combine them into a nonsensical block of text and throw it up on the Web to grab eyeballs and advertising dollars.Google believes that, if scrapers succeed too often, consumers will lose confidence in search and turn to other resources, thus posing an existential threat to the company.Regulators in the U.S. and abroad have been looking into various aspects of Google's business practices since the company's 2007 purchase of ad firm DoubleClick. At the moment, European regulators are conducting an antitrust inquiry into Google's search business while the Federal Trade Commission is doing likewise. Google relies overwhelmingly on its core product, Internet search, and dominates the market for that product. It handles around two-thirds of U.S. Internet searches and more than 80 percent in many European countries, according to comScore Inc.

CAIRO, July 4 (Xinhua) -- U.S. and Italian archeologists have discovered the oldest description about an Egyptian king (about 3, 200 BC) in Egypt's Aswan, Egyptian Antiquities Minister Zahi Hawass said on Monday.The engravings "traces back to when the Egyptian language firstly recorded in hieroglyphs and tells about a unique complete royal ceremony which was known in the ancient Egyptian era," said Hawass in a statement."The pharaoh appears to be wearing the Upper Egypt crown accompanied by (Horus apostles) at the royal court, " Hawass added.Horus is one of the oldest and most significant deities in the ancient Egyptian religion and was worshipped from at least the late Predynastic period through to Greco-Roman times."This discovery is considered a supplementary one at the site unearthed near in el-Hamdulab site in northern Aswan, archaeologists said.This is one of the latest discoveries in Egypt as the surrounding wall of Betah temple (1550 BC-1070 BC) and a gate traces back to Shabaka king era were unearthed on Saturday in Luxor.

VIENNA, Sept. 9 (Xinhua) -- The three-day Traditional Chinese Medicine (TCM) exhibition opened Friday in the Flower Garden Hirschstetten in Vienna, with the aim to introduce traditional Chinese medicine to the Austrians and to arouse their interest in the culture of Chinese medicine.Holding for the second time, the exhibition this year have attracted more visitors to take part in the health talks on traditional Chinese medicine, read or buy books around the theme of traditional Chinese medicine. Some visitors enthusiastically tried Chinese diet therapy prepared by the organizers.In recent years, traditional Chinese medicine has been increasingly recognized and accepted in Austria. It has already not only entered into the classroom but also into the hospital and clinic.Some private health insurance companies in Austria have started to include the treatment by traditional Chinese medicine into their insuring categories. Chinese patent drugs are already available in many pharmacies in Austria.But in general, traditional Chinese medicine still faces many limits in Austria, which hasn't been involved into the public health insurance system. Some Austrians still have doubts of Chinese medicine, in particular the medicinal herb drugs. All these have restricted the development of traditional Chinese medicine here.Currently, major clinics of traditional Chinese medicine carry out only acupuncture and moxibustion, massage and other health-care physical therapy.Richard Schmerker, a doctor of traditional Chinese medicine in Austria, told reporters that the development of traditional Chinese medicine here still faces many challenges and the biggest one is the shortage of effective propaganda and popularization.But he expressed his full confidence about the future of traditional Chinese medicine in Austria. He said, the uniqueness of finding the root cause of diseases and laying the axe to the root will make it be accepted by more and more Austrians.

WASHINGTON, Aug. 4 (Xinhua) -- U.S. scientists have found two gene mutations occurring in oligodendrogliomas, the second-most common form of brain cancer, according to a study to be published Friday in journal Science.For years scientists have been looking for the primary cancer genes involved in oligodendrogliomas evolvement. Scientists know the two chromosomes held the probable mutations, but the particular gene information remains unclear.Now scientists at Duke University Medical Center and Johns Hopkins University have discovered the most likely genetic mutations that researchers have been hunting for on chromosomes 1 and 19.The genes they identified, CIC or FUBP1, are tumor suppressor genes. The cancer-related pathways that involve these genes could become targets for future treatments, said Hai Yan, a Duke associate professor of pathology and co-corresponding author of the study.The researchers found CIC on chromosome 19 and FUBP1 on chromosome 1 based on an initial study of seven oligodendrogliomas. They found six mutations and two mutations, respectively, in the seven tumors. Further study of 27 more of these tumors showed that there were 12 and three mutations of CIC and FUBP1, respectively. The two genes were rarely mutated in other types of cancers, indicating that they are oligodendroglioma-specific genes.These genes were difficult to find until the technology improved, said Yan."The team used whole genome sequencing technology so that no genes would be excluded, and we found to our surprise that one gene, on chromosome 19, was mutated in six out of the seven initial tumor specimens we sequenced," Yan said. "A mutation frequency of 85 percent is very high."The finding of two additional new genes involved in oligodendrogliomas increases the chances for an effective combination drug therapy for the tumor, Yan said. He envisions a combination cocktail of drugs similar to the combination-drug treatments taken by HIV patients that would target different pathways involved in cancer, and assist both in reducing the chance of relapsing and increasing odds of success.